TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04529629

Intervention type: OTHER
Intervention: surgery or drug
Description: pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results

Intervention type: OTHER
Intervention: surgery or drug
Description: pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results

Intervention type: OTHER
Intervention: surgery or drug
Description: pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results
Study: NCT05589935

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relief Study Product Usage
Description: Participants instructed to use study product daily as directed for a period of 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Relief Study Product Usage
Description: Participants instructed to use study product daily as directed for a period of 4 weeks
Study: NCT06297330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep
Description: The sleep management intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators related to the sleep and fatigue levels will be recorded to assess the progress of each student.
Study: NCT05596929

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial intelligence
Description: After the patients under triage classification to which randomly allocates in two groups. The group with AI intervention and the other without AI intervention.
Study: NCT06670430

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: This group will include 30 type II diabetic patients with peripheral neuropathy Patients will receive placebo TENS and NMES for 30-min sessions, 3 days per week, for 10 weeks with medical treatment
Study: NCT06670196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: 4mg/kg, intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: 80mg, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80mg, QD
Study: NCT06677541

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructional handout
Description: A handout on how to improve sexual dysfunction/function will be provided

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructional handout
Description: A handout on how to improve sexual dysfunction/function will be provided

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrator
Description: An FDA approved vibrator device to improve sexual function will be provided
Study: NCT06676319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lunsekimig
Description: Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-Acting Beta Agonists (SABA)
Description: Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Short-Acting Beta Agonists (SABA)
Description: Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol
Description: Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone/salmeterol
Description: Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Description: Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide/formoterol
Description: Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
Study: NCT06204926

Intervention type: DIAGNOSTIC_TEST
Intervention: AI diagnostic algorithm
Description: The SMILE procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
Study: NCT06619093

Intervention type: OTHER
Intervention: blood sampling
Description: 3 additional citrate tubes (2.7mL)

Intervention type: OTHER
Intervention: blood sampling
Description: 3 additional citrate tubes (2.7mL)
Study: NCT06619509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigimadlin
Description: Brigimadlin
Study: NCT06670729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quran listening
Description: listening to quran recitation via head phone

Intervention type: OTHER
Group type: OTHER
Intervention: silent headphones group
Description: headphones were silent, patient do not listen to any thing
Study: NCT05496140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLS-R-FUERTE
Description: The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
Study: NCT06619860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to pregabalin)
Description: Placebo matched to pregabalin for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matched to VX-993)
Description: Placebo matched to VX-993 for oral administration.
Study: NCT06618326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Twenty patients were suffering from functional constipation. They ranged in age from 7-15 years. All children had reasonable cognitive functions, and a reasonable IQ so as were able to follow the instructions. All received acupuncture regardless of the number of acupuncture points, frequency, and courses of treatment in addition to non-pharmacological treatment advice from health care authorities such as the British Nutrition Foundation includes increasing fluid intake, physical activity and increasing dietary fiber consumption to a recommended daily intake of 30 g

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biofeedback
Description: Twenty patients were suffering from functional constipation. They ranged in age from 7-15 years. All children had reasonable cognitive functions, and a reasonable IQ so as were able to follow the instructions. All received biofeedback training in addition to non-pharmacological treatment advice from health care authorities such as the British Nutrition Foundation includes increasing fluid intake, physical activity and increasing dietary
Study: NCT06186414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0237
Description: Several dose levels of SIM0237 will be administered as a single agent for evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0237 and BCG
Description: Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0237
Description: RD level of SIM0237 will be administered as a single agent for evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0237
Description: RD level of SIM0237 will be administered as a single agent for evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0237 and BCG
Description: RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0237 and BCG
Description: RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
Study: NCT06067438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone Hydrochloride
Description: Given IV and via feeding tube

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Given IV
Study: NCT06627933

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05292170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat acclimation
Description: 10 consecutive days of heat acclimation
Study: NCT05092061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-repetition resistance training
Description: Will undertake resistance training with moderate loads, and moderate repetitions 3 times per week for 7 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-repetition resistance training
Description: Will undertake resistance training with low loads, and high repetitions 3 times per week for 7 weeks.
Study: NCT05702359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g glucose diluted in 300mL water, tested two times, in different visits, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control juice
Description: Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from control juice (consisted of pomegranate, grape, apple and orange), tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Juice with vitamin D3
Description: Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing vitamin D3, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Juice with n-3 fatty acids
Description: Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing n-3 fatty acids, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Juice with probiotics
Description: Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing probiotics, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Juice with probiotics, vitamin D3, and n-3 fatty acids
Description: Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing probiotics, vitamin D3 and n-3 fatty acids, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
Study: NCT05153356

Intervention type: DEVICE
Intervention: Personal Kinetigraph, Kinesia 360
Description: 10 patients will be assigned to each technology with a crossover at 3 months for a total of 20 patients over 6 months, 6 timepoints with data collected every 2 weeks.
Study: NCT06324253

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral Erector spine block,A dose of 30 ml 0.125% Bupivacaine will be injected.
Description: will receive bilateral Erector Spinae Block after induction of anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: will receive Thoracic Epidural Block before induction of anesthesia .a bolus dose of 10 ml of 0.125% bupivacaine through epidural catheter followed by continuous infusion of 0.125% bupivacaine at the rate of 0.1 ml/kg/hour
Study: NCT06358352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein / Zeaxanthin
Description: lutein extract from lutein oral capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: platelet rich fibrin extracted from patient's blood after centrifuging
Study: NCT06482593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc-Oxide Eugenol Sealer
Description: Zinc oxide-eugenol sealers have a slow setting time, shrinkage while setting, solubility, and can discolour tooth structure. This sealer group has an advantage in terms of antibacterial activity.It will absorb if extruded into the periradicular tissues.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AH-Plus Epoxy Resin Sealer
Description: Dentsply AH Plus Root Canal Sealing Material is a two-component paste/paste root canal sealer based on epoxy-amine resin. The AH Plus sealer shows extremely low shrinkage making it a suitable choice of material to seal the root canal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bio-C Sealer
Description: Bio-C® Sealer is a ready-to-use, bioceramic root canal sealer with biologically active ingredients to seal and heal the root canal space. Bio-C Sealer's mechanical and physical properties make it easy to manipulate and seal the canals, while its biological properties and high pH ensure safety and treatment success.
Study: NCT04832074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Real Dry Needling in the most active Myofascial Trigger Point

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: Sham Dry Needling in the same location, but not piercing the skin
Study: NCT05668871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danning Tablet
Description: 3 times each day, 5 tablets each time, take orally after meals.
Study: NCT06200961

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transnasal Endoscopy
Description: Unsedated endoscopic evaluation through the nose.
Study: NCT06694311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: 12 cmH2O for 48 hours (at least 10 hours of therapy per day). Nasobucal interface will be the preferred route with complete facial mask being also an acceptable device. If needed, therapy breaks will be delivered with HFNO at 50 L/min.~Non-invasive ventilation will not be allowed.~After 48 hours of treatment, clinicians will be able to decide the respiratory support to be provided although CPAP will be recommended to be continued as long as PaO2/FiO2 is less than or equal to 300 and inspired oxygen fraction is 40% or more.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNO 50 L/min
Description: HFNO 50 L/min for 48 hours. Therapy breaks with oxygen facemask will be allowed as per clinician decision but the protocol will advise against this practice.~Non-invasive ventilation will not be allowed.~After 48 hours of treatment, clinicians will be able to decide the respiratory support to be provided although HFNO will be recommended to be continued as long as PaO2/FiO2 is less than or equal to 300 and inspired oxygen fraction is 40% or more.
Study: NCT06200961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy
Description: Sedated endoscopic evaluation through the mouth.
Study: NCT05890456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Students with Involved Families and Teacher Program
Description: The SWIFT Program is a 9-12 month intervention that includes four components: (a) behavioral progress monitoring, (b) clinical supervision of the intervention elements and coordination with the school, (c) parent support to promote parent engagement/collaboration with the school and study routines in the home, and (d) behavioral skills coaching for students.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services As Usual
Description: The SAU students and families will continue to receive any services that they were receiving prior to their entry into the study. These may include school-based interventions and supports and related services as required in the student's Individualized Education Program.
Study: NCT06180096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat film coated tablets
Description: 1 tablet of 2.5 mg Riociguat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat film coated tablets
Description: 1 tablet of 2.5 mg Riociguat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adempas Filmtabletten
Description: 1 tablet of 2.5 mg Riociguat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adempas Filmtabletten
Description: 1 tablet of 2.5 mg Riociguat
Study: NCT06482398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sericin extract and turmeric extract cream
Description: Apply the sample 2 times a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide 1% Cream
Description: Apply the sample 2 times a day for 8 weeks
Study: NCT04735601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ahmed Valve
Description: Ahmed valve implantation coated with poly lactic -co-glycolic acid (PLGA) saturated with Mitomycin-C in the management of adult onset glaucoma in Sturge Weber syndrome

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Valve
Description: Ahmed valve implantation coated with poly lactic -co-glycolic acid (PLGA) saturated with Mitomycin-C in the management of adult onset glaucoma in Sturge Weber syndrome
Study: NCT06150378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Patients that receive an injection with corticosteroid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plathet rich plasma
Description: Patients that receive an injection with Plathet-rich plasma
Study: NCT06695546

Intervention type: OTHER
Intervention: VExUS evaluation ultrasound
Description: VExUS evaluation by ultrasound will be performed before the filling/bleeding/cleaning procedure, and again after the procedure:~* Inferior vena cava measurement in Time-Motion (TM) mode, 1-2 cm from the right atrial orifice.~* Hepatic venous Doppler measurement in pulsed Doppler mode.~* Renal vein Doppler measurement in pulsed Doppler mode. Each measurement is performed three times consecutively (to average the results), then the ultrasound measurements are compiled into a score according to the degree of doppler severity.
Study: NCT05743283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynEx Wound Cleanser
Description: SynEx is a concentrated form of SynePure®, an FDA 510(k) cleared aqueous, osmotically balanced wound cleanser containing patented chitosan derivatives. The ingredients are USP purified water, chitosan arginine (a patented chitosan derivative), sorbitol powder, and betaine. SynEx cleanser is packaged in a collapsible plastic pouch for reconstitution in water before debriding and cleansing a wound.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: The saline solution is composed of water and salt. It is packaged in a collapsible plastic pouch.